Slide 1: Full Year 2022 Results Presentation
• FULL YEAR 2022 RESULTS PRESENTATION • March 21st, 2023
Slide 2: Executive Summary
Executive Summary
Slide 3: GVS – FY 2022 Results At-a-Glance
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx GVS – FY 2022 Results At-a-Glance Flat organic growth in a post COVID environment, pressure on margins SALES EBITDA Adjusted and % NFP and Leverage €m €m €m +14
Slide 4: GVS – 4Q 2022 Results At-a-Glance
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx GVS – 4Q 2022 Results At-a-Glance On the recovery path post 3Q lows, profitability on its way back SALES Breakdown by Division EBITDA Adjusted and % EBIT Adjust
Slide 5: 4Q and Full Year 2022 Financials Review
4Q and Full Year 2022 Financials Review
Slide 6: 4Q 2022 Results Review – Focus on EBITDA and NFP
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx 4Q 2022 Results Review – Focus on EBITDA and NFP EBITDA driven by sales increase, NFP by NWC control EBITDA – Q3 2022 TO Q4 2022 BRIDGE €m • €5.1m increase in E
Slide 7: FY 2022 Results Review – Focus on Sales
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2022 Results Review – Focus on Sales Despite flat performance in FY22, solid 6.7% organic 2019-22 sales CAGR SALES BREAKDOWN – ORGANIC VS. M&A AND DISP. MASK
Slide 8: FY 2022 Results Review – Focus on Sales
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2022 Results Review – Focus on Sales Sound organic growth across divisions Healthcare & Life Sciences Health & Safety Energy & Mobility €m 245.4 245.4 €m €m
Slide 9: FY 2022 Results Review – Focus on Profitability
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2022 Results Review – Focus on Profitability Loss of volumes and lower fixed costs absorption led to margin dilution ADJ. EBITDA BREAKDOWN – ORGANIC VS. M&A
Slide 10: FY 2022 Results Review – Focus on Debt
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2022 Results Review – Focus on Debt Deleverage in progress. Shareholder loan as additional liquidity buffer Net Debt Evolution and Leverage Shareholder Loan
Slide 11: Focus on FY 2022 M&A: STT and Haemotronic
Focus on FY 2022 M&A: STT and Haemotronic
Slide 12: Focus on FY2022 M&A: STT
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Focus on FY2022 M&A: STT The gateway to the attractive Chinese hospital market Penetrate the Chinese hospitals market Expand GVS product portfolio in the blood
Slide 13: Focus on FY2022 M&A: Haemotronic
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Focus on FY2022 M&A: Haemotronic New products and technologies in the strategic infusion segment Strengthening presence in the blood infusion segment New produc
Slide 14: Strategic considerations
Strategic considerations
Slide 15: Roadmap for Profitability Recovery
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Roadmap for Profitability Recovery Key issues and remedial actions ISSUES AFFECTING PROFITABILITY REMEDIAL ACTIONS Price increase to offset cost inflation in Co
Slide 16: Roadmap for Profitability Recovery – Special projects
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Roadmap for Profitability Recovery Special projects Project Activities Description BUs involved ▪ Findlay Findlay // ▪ Findlay rationalization: part of Findlay
Slide 17: 2023 Outlook and Guidance
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx 2023 Outlook and Guidance Growth and profitability recovery set to continue, despite challenges Market environment remains uncertain, on the back of geopolitica
Slide 18: FY 2022 Results Presentation – Final Takeaways
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2022 Results Presentation – Final Takeaways Our commitment for delivery GVS confirmed the resiliency of its organic business, but the profitability was hit b
Slide 19: Appendix – Support Material
Appendix – Support Material
Slide 20: FY 2021 and 2022 P&L – Statutory Adjusted View
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2022 Results Review FY 2021 and 2022 P&L – Statutory Adjusted View of which FY 2021 of which FY 2022 €m FY2021 % FY2022 % non-recurring Adjusted non-recurrin
Slide 21: Reclassified Balance Sheet - FY 2021 – FY 2022
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2022 Results Review Reclassified Balance Sheet - FY 2021 – FY 2022 FY2021 FY2022 €m Net intangible fixed assets 227.7 494.8 Net usage rights 10.4 23.0 Net ta
Slide 22: Cash Flow Statement - FY 2021 – FY 2022
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2022 Results Review Cash Flow Statement - FY 2021 – FY 2022 €m FY2021 FY2022 Pre-tax result 89.8 34.6 Amortisation, depreciation and writedowns 23.5 38.0 Cap
Slide 23: Disclaimer
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Disclaimer Pursuant to art. 154-bis, paragraph 2, of the Italian Unified Financial Act of February 24, 1998, the executive in charge of preparing the corporate